Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis
Open Access
- 29 April 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 16 (4) , e1002797
Abstract
The efficacy, safety, and clinical importance of extended-duration thromboprophylaxis (EDT) for prevention of venous thromboembolism (VTE) in medical patients remain unclear. We compared the efficacy and safety of EDT in patients hospitalized for medical illness. Electronic databases of PubMed/MEDLINE, EMBASE, Cochrane Central, and ClinicalTrials.gov were searched from inception to March 21, 2019. We included randomized clinical trials (RCTs) reporting use of EDT for prevention of VTE. We performed trial sequential and cumulative meta-analyses to evaluate EDT effects on the primary efficacy endpoint of symptomatic VTE or VTE-related death, International Society on Thrombosis and Haemostasis (ISTH) major or fatal bleeding, and all-cause mortality. The pooled number needed to treat (NNT) to prevent one symptomatic or fatal VTE event and the number needed to harm (NNH) to cause one major or fatal bleeding event were calculated. Across 5 RCTs with 40,247 patients (mean age: 67–77 years, proportion of women: 48%–54%, most common reason for admission: heart failure), the duration of EDT ranged from 24–47 days. EDT reduced symptomatic VTE or VTE-related death compared with standard of care (0.8% versus 1.2%; risk ratio [RR]: 0.61, 95% confidence interval [CI]: 0.44–0.83; p = 0.002). EDT increased risk of ISTH major or fatal bleeding (0.6% versus 0.3%; RR: 2.04, 95% CI: 1.42–2.91; p < 0.001) in both meta-analyses and trial sequential analyses. Pooled NNT to prevent one symptomatic VTE or VTE-related death was 250 (95% CI: 167–500), whereas NNH to cause one major or fatal bleeding event was 333 (95% CI: 200–1,000). Limitations of the study include variation in enrollment criteria, individual therapies, duration of EDT, and VTE detection protocols across included trials. In this systematic review and meta-analysis of 5 randomized trials, we observed that use of a post-hospital discharge EDT strategy for a 4-to-6-week period reduced symptomatic or fatal VTE events at the expense of increased risk of major or fatal bleeding. Further investigations are still required to define the risks and benefits in discrete medically ill cohorts, evaluate cost-effectiveness, and develop pathways for targeted implementation of this postdischarge EDT strategy. PROSPERO CRD42018109151.Keywords
This publication has 21 references indexed in Scilit:
- Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical PatientsNew England Journal of Medicine, 2016
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical PatientsNew England Journal of Medicine, 2013
- Prevention of VTE in Nonsurgical PatientsChest, 2012
- Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill PatientsNew England Journal of Medicine, 2011
- Quantifying Selective Reporting and the Proteus Phenomenon for Multiple Datasets with Similar BiasPLOS ONE, 2011
- Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced MobilityAnnals of Internal Medicine, 2010
- Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims Analysis From 30 Managed Care OrganizationsJournal of Managed Care Pharmacy, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Cumulative Meta-Analysis of Therapeutic Trials for Myocardial InfarctionNew England Journal of Medicine, 1992